Maternal and perinatal outcomes of a venous thromboembolism high-risk cohort using a multidisciplinary treatment approach

Int J Gynaecol Obstet. 2021 Sep;154(3):500-507. doi: 10.1002/ijgo.13628. Epub 2021 Feb 20.

Abstract

Objective: To evaluate the maternal and perinatal outcomes in a cohort of pregnant women at high risk of venous thromboembolism (VTE).

Methods: Women at high risk of VTE were evaluated in a multidisciplinary program using a complete diagnostic workup, and specific prophylactic or therapeutic treatment.

Results: Women were considered at high risk of VTE in 57% (85/148) because of prior (75) or current (10) thromboembolism, and in 27% (40/148) of the cases due to adverse obstetric history. Thrombophilia was diagnosed in 57% of the cases (85/148), either in patients with previous thromboembolism (48%, 41/85) or without a history of thrombosis (70%, 44/63). The most common thrombophilia was antiphospholipid syndrome in 34% (29/85) of the cases. Under respective prophylactic or therapeutic treatment, there were no VTE during pregnancy (0%, 0/148), whereas four events occurred during the puerperium (3%, 4/148). An adverse obstetric outcome was present in 5% (7/148) of all pregnancies, with four early spontaneous abortions (3%, 4/148) and three late miscarriages (2%, 3/148).

Conclusion: Pregnant women at high risk of VTE can be effectively managed using a risk-adapted treatment. Our results support prospective enrollment and a multidisciplinary assessment of VTE in high-risk pregnant women.

Keywords: acquired thrombophilias; antiphospholipid syndrome; low-molecular-weight heparin; perinatal outcome; pregnancy; thromboprophylaxis; venous thromboembolism.

MeSH terms

  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome*
  • Female
  • Humans
  • Pregnancy
  • Prospective Studies
  • Risk Factors
  • Thrombophilia*
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / etiology
  • Venous Thromboembolism* / therapy

Substances

  • Anticoagulants